|1.||Bedenić, Branka: 3 articles (08/2015 - 12/2014)|
|2.||Uzunović, Selma: 3 articles (08/2015 - 12/2014)|
|3.||Kamberović, Farah: 3 articles (08/2015 - 12/2014)|
|4.||Ibrahimagić, Amir: 3 articles (08/2015 - 12/2014)|
|5.||Song, Wonkeun: 3 articles (12/2006 - 01/2004)|
|6.||Hanson, Nancy D: 3 articles (08/2006 - 06/2002)|
|7.||Budimir, Ana: 2 articles (08/2015 - 12/2014)|
|8.||Rijnders, Michelle I A: 2 articles (08/2015 - 12/2014)|
|9.||Stobberingh, Ellen E: 2 articles (08/2015 - 12/2014)|
|10.||Karlowsky, James A: 2 articles (01/2014 - 10/2009)|
01/01/2003 - "The present study was undertaken to study the occurrence of multidrug resistant and AmpC beta-lactamase producing Klebsiella spp. and Escherichia coli in children less than five years of age as this age group is very susceptible to intestinal and extraintestinal infections. "
12/01/2014 - "Emergency (clonal spread) of methicillin-resistant Staphylococcus aureus (MRSA), extended spectrum (ESBL)--and AmpC beta-lactamase-producing Gram-negative bacteria infections at Pediatric Department, Bosnia and Herzegovina."
10/01/2009 - "coli harbouring ESBLs, AmpC beta-lactamases and CRS when simulating clinically achievable serum concentrations, and represents a potential therapy for infections caused by these isolates."
07/01/2009 - "A case-control study was performed with the objective of analysing risk factors and clinical features of infections caused by plasmid-mediated AmpC beta-lactamase (plasmid AmpC)-producing Enterobacteriaceae. "
07/01/2009 - "Risk factors and clinical features of infections caused by plasmid-mediated AmpC beta-lactamase-producing Enterobacteriaceae."
|2.||Cross Infection (Nosocomial Infection)
12/01/2005 - "Detection of plasmid-mediated (P-M) AmpC beta-lactamase-producing isolates is considered critical for epidemiologic studies and hospital infection control, but the documents of the Clinical and Laboratory Standards Institute do not contain any recommendation for the phenotypic detection. "
01/01/2009 - "Phenotyping of potential AmpC-beta-lactamases producers of Enterobacteriaceae and molecular mechanisms of resistance to beta-lactams of Enterobacter cloacae strains, isolated in cases of nosocomial infections]."
12/01/2005 - "The continued efficacy of carbapenems such as meropenem confirms that these remain first-line agents for treatment of nosocomial infections caused by Enterobacteriaceae-producing ESBL or AmpC beta-lactamases."
09/01/2009 - "Nosocomial infections caused by this organism are often hard to treat because of both the intrinsic resistance of the species (it has constitutive expression of AmpC beta-lactamase and efflux pumps, combined with a low permeability of the outer membrane), and its remarkable ability to acquire further resistance mechanisms to multiple groups of antimicrobial agents, including beta-lactams, aminoglycosides and fluoroquinolones. "
|3.||Urinary Tract Infections (Urinary Tract Infection)
05/01/2015 - "High prevalence of CTX-M-15 and first report of CTX-M-3, CTX-M-22, CTX-M-28 and plasmid-mediated AmpC beta-lactamase producing Enterobacteriaceae causing urinary tract infections in Bosnia and Herzegovina in hospital and community settings."
03/13/2015 - "Plasmid-mediated AmpC beta-lactamase-producing Escherichia coli causing urinary tract infection in the Auckland community likely to be resistant to commonly prescribed antimicrobials."
01/01/2014 - "Given the abundant clinical experience with ceftazidime and the significant improvement that avibactam provides in its activity against contemporary β-lactamase-producing Gram-negative pathogens, it is likely this new combination agent will play a role in the empiric treatment of complicated urinary tract infections (monotherapy) and complicated intra-abdominal infections (in combination with metronidazole) caused or suspected to be caused by antimicrobial-resistant pathogens (eg, extended spectrum beta-lactamase-, AmpC-, or Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae and multidrug-resistant P. "
01/01/2003 - "We report the description of a novel plasmid-encoded AmpC beta-lactamase gene (blaCMY-10) from Enterobacter aerogenes K9911729 that was isolated from a patient suffering from pneumonia in South Korea. "
08/01/1999 - "A novel type of AmpC beta-lactamase, ACC-1, produced by a Klebsiella pneumoniae strain causing nosocomial pneumonia."
06/01/2006 - "Effect of porins and plasmid-mediated AmpC beta-lactamases on the efficacy of beta-lactams in rat pneumonia caused by Klebsiella pneumoniae."
06/01/2006 - "The in vivo activities of imipenem, meropenem, and cefepime were studied in a model of rat pneumonia caused by a plasmid-mediated AmpC beta-lactamase ACT-1-producing Klebsiella pneumoniae strain (K. "
11/21/2003 - "Multidrug-resistant Pseudomonas aeruginosa strains harbouring R-plasmids and AmpC beta-lactamases isolated from hospitalised burn patients in a tertiary care hospital of North India."
12/01/2014 - "Determination of extended spectrum beta-lactamases, metallo-beta-lactamases and AmpC-beta-lactamases among carbapenem resistant Pseudomonas aeruginosa isolated from burn patients."
12/31/2013 - "Coexistence of Extended Spectrum Beta-Lactamases, AmpC Beta-Lactamases and Metallo-Beta-Lactamases in Acinetobacter baumannii from burns patients: a report from a tertiary care centre of India."
12/01/2006 - "pneumoniae isolates co-producing an SHV-2a ESBL and a DHA-1 AmpC beta-lactamase in a Korean hospital, which were suggested to represent a single clonal spread at a burns ICU. "
|4.||Carbapenems (Carbapenem Antibiotics)
|10.||Anti-Bacterial Agents (Antibiotics)